ChickenStockChickenStock

AI English summary of an SEC filing — figures as filed

Boston Scientific logoBoston Scientific BSX

Boston Scientific announced on October 7, 2026 that Joe Fitzgerald, who currently serves as Executive Vice President and Group President, Cardiovascular, has been promoted to Executive Vice President and Chief Operating Officer, effective January 1, 2027.

8-KDeparture or Appointment of Directors or Certain OfficersFiled Period of report Summary published (UTC)

Key points

AI summary

  1. Boston Scientific announced on October 7, 2026 that Joe Fitzgerald, who currently serves as Executive Vice President and Group President, Cardiovascular, has been promoted to Executive Vice President and Chief Operating Officer, effective January 1, 2027.

  2. The company said that under the terms of Fitzgerald's Offer Letter, effective January 1, 2027, he will receive an annual base salary of $1,050,000, an annual bonus target percentage equal to 110% of his base salary, and an annual equity award for 2027 with a total grant date fair value of $7,000,000.

  3. In connection with Fitzgerald's appointment as COO, the company said it will establish three reportable segments—Interventional Therapies, Rhythm Solutions and MedSurg—effective January 1, 2027. The company explained that this structure is designed to enable faster decision making and support strategic allocation of investments across its portfolio.

  4. The company said the Board of Directors appointed Mark Bickel as Senior Vice President, Global Accounting Controller and Chief Accounting Officer, effective March 1, 2027, on October 1, 2026. Emily Woodworth will step down from the Chief Accounting Officer position on the same day, and the company said this transition is not due to any disagreement with the company on any matter relating to its financial statements, internal control over financial reporting, operations, policies or practices.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Joe Fitzgerald Chief Operating Officer effective January 1, 2027

Boston Scientific announced on October 7, 2026 that Joe Fitzgerald, who currently serves as Executive Vice President and Group President, Cardiovascular, has been promoted to Executive Vice President and Chief Operating Officer, effective January 1, 2027.

Source · Based on the filing body and exhibits

Fitzgerald's annual base salary $1,050,000 and 2027 equity award $7,000,000

The company said that under the terms of Fitzgerald's Offer Letter, effective January 1, 2027, he will receive an annual base salary of $1,050,000, an annual bonus target percentage equal to 110% of his base salary, and an annual equity award for 2027 with a total grant date fair value of $7,000,000.

Source · Based on the filing body and exhibits

Three reportable segments effective January 1, 2027

In connection with Fitzgerald's appointment as COO, the company said it will establish three reportable segments—Interventional Therapies, Rhythm Solutions and MedSurg—effective January 1, 2027. The company explained that this structure is designed to enable faster decision making and support strategic allocation of investments across its portfolio.

Source · Based on the filing body and exhibits

Mark Bickel Chief Accounting Officer effective March 1, 2027

The company said the Board of Directors appointed Mark Bickel as Senior Vice President, Global Accounting Controller and Chief Accounting Officer, effective March 1, 2027, on October 1, 2026. Emily Woodworth will step down from the Chief Accounting Officer position on the same day, and the company said this transition is not due to any disagreement with the company on any matter relating to its financial statements, internal control over financial reporting, operations, policies or practices.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗
Source: SEC EDGAR (U.S. Securities and Exchange Commission). Item captions are the SEC's. The summary is for reference only and is not investment advice.